var data={"title":"Danaparoid (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Danaparoid (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5974?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=danaparoid-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Danaparoid (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156561\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Orgaran</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156590\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Heparinoid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156563\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing recommendations per manufacturer labeling unless otherwise noted. Dose expressed as anti-Xa units.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of DVT following orthopedic, major abdominal, or thoracic surgery:</b> SubQ: 750 units twice daily for up to 14 days; it is recommended that patients begin prophylactic therapy preoperatively and receive their last preoperative dose 1 to 4 hours before surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of DVT in stroke (nonhemorrhagic):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: IV: Up to 1,000 units as single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: SubQ: 750 units every 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIT:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prevention of DVT (with current or past HIT):</i> <b>Note:</b> May administer IV bolus of 1,250 units if clinically necessary (ie, current HIT) or may initiate maintenance regimen without a bolus as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;90 kg: Current HIT or past HIT: 750 units every 8 to 12 hours for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;90 kg: Current HIT: 1,250 units every 8 to 12 hours for 7 to 10 days; Past HIT: 1,250 units every 12 hours or 750 units every 8 hours  for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment of DVT/PE (see also Linkins 2012):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial  IV bolus: Thrombosis &lt;5 days old:  &le;55 kg: 1,250 to 1,500 units; 55 to 90 kg: 2,250 to 2,500 units; &gt;90 kg: 3,750 units; followed by a  maintenance IV infusion or maintenance SubQ injections. <b>Note:</b> If thrombosis is &ge;5 days old, administer an IV bolus dose of 1,250 units followed by maintenance SubQ injections.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: IV infusion (after IV bolus administered): Thrombosis &lt;5 days old: 400 units/hour for 4 hours, then 300 units/hour for 4 hours, then 150 to 200 units/hour for 5 to 7 days; adjust rate according to target anti-Xa levels</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: SubQ injections (after IV bolus administered):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Thrombosis &lt;5 days old: &le;55 kg: 1,500 units every 12 hours; 55 to 90 kg: 2,000 units every 12 hours; &gt;90 kg: 1,750 units every 8 hours for 4 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Thrombosis &ge;5 days old: &le;90 kg: 750 units every 8 to 12 hours; &gt;90 kg: 750 units every 8 hours or 1,250 units every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIT/surgical thromboprophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nonvascular surgery:</i> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;90 kg: 750 units 1 to 4 hours preoperatively and at &ge;6 hours postop, followed by 750 units every 12 hours beginning day 1 post-op and continued for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;90 kg: 750 units 1 to 4 hours preoperatively and at &ge;6 hours postop, followed by 750 units every 8 hours or 1,250 units every 12 hours beginning day 1 post-op and continued for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Embolectomy: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">55 to 90 kg: IV: 2,250 to 2,500 units as a bolus preoperatively, followed by SubQ: 1,250 units every 12 hours beginning &ge;6 hours postop. <b>Note:</b> After several days of therapy, may switch to a lower SubQ dose of 750 units every 8 to 12 hours or oral anticoagulant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;90 kg: IV: 2,250 to 2,500 units as a bolus preoperatively, followed by 150 to 200 units/hour beginning &ge;6 hours post-op for 5 to 7 days. <b>Note:</b> After several days of IV therapy, may switch to SubQ: 750 units every 8 to 12 hours or oral anticoagulant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIT/cardiac procedures: Note:</b> Other therapies may be preferred (eg, bivalirudin); long half-life and irreversibility of danaparoid make it a poor choice in these settings. Refer to product labeling for dosing recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Catheter patency:</b> Mix 750 units with 50 mL normal saline. Flush catheter with 5 to 10 mL of resulting solution as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Conversion to oral anticoagulant therapy (OAC):</b> Establish adequate antithrombotic effect with danaparoid prior to initiation of oral anticoagulant (OAC) therapy. PT/INR should be therapeutic before discontinuing use of danaparoid. <b>Note:</b> Laboratory values taken within 5 hours of danaparoid administration may be unreliable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion of SubQ danaparoid to OAC (based on current danaparoid dose):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Danaparoid 750 units every 12 hours: Initiate OAC and maintain danaparoid therapy until PT/INR is therapeutic; may take up to 5 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Danaparoid 1,250 units every 12 hours: Initiate OAC and decrease danaparoid to 750 units every 12 hours; maintain danaparoid therapy until PT/INR is therapeutic; may take up to 5 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion of IV danaparoid to OAC:</i> Initiate OAC with concurrent danaparoid IV infusion (maximum 300 units/hour); discontinue IV infusion once INR is therapeutic (maximum INR: 3.0). If bleeding risk is present, IV infusion should be reduced to 75 units/hour and OAC initiation withheld for 24 hours <b>or</b> danaparoid IV infusion may be switched to subcutaneous route at a dose of 1,250 units every 12 hours and the recommended conversion of SubQ danaparoid to OAC regimen followed (ie, subsequent reduction to 750 units every 12 hours while OAC initiated).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156580\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing recommendations per manufacturer labeling unless otherwise noted. Dose expressed as anti-Xa units.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute thrombosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment: IV: Initial: 30 units/kg as a bolus; Maintenance: 1.2 to 4 units/kg/hour.  <b>Note:</b> Anticipated plasma anti-Xa levels after bolus: 400 to 700 units/L; steady-state levels: 400 to 600 units/L (or 500 to 800 units/L for higher doses).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis: SubQ: 10 units/kg every 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156564\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156565\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Danaparoid half-life is significantly prolonged in renal impairment; anti-Xa levels should be closely monitored. Dosage reduction, especially with maintenance doses, may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild or moderate impairment: There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (serum creatinine &ge;220 micromol/L [&ge;2.5 mg/dL]): Following initial dose, dose reductions or temporary discontinuation of therapy may be necessary to prevent accumulation of plasma anti-Xa (indicated by consistent, steady state-plasma anti-Xa activity &gt;0.5 anti-Xa units).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: IV: 1,500 to 3,750 units before dialysis session. <b>Note:</b> Dose depends on frequency of dialysis regimen (eg, daily dialysis vs every-other-day or less frequently) and weight of patient with the lower dose recommended for patients &lt;55 kg. Do not administer prior to dialysis if plasma antifactor Xa levels &gt;400 units/L and not receiving daily dialysis; however, if fibrin threads are present in bubble chamber may administer 1,500 units.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First two dialysis sessions:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;10 years: 30 units/kg <i>plus</i> 1,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">10 to 17 years: 30 units/kg <i>plus</i> 1,500 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third and subsequent sessions (based on predialysis anti-Xa levels):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;300 units/L: Administer previous dialysis dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">300 to 500 units/L: Reduce total dose by 250 units</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;500 units/L: No dose required with next dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemofiltration: Adults: IV: 55 to 90 kg: 2,500 units as a bolus, followed by 600 units/hour for 4 hours, then 400 units/hour for 4 hours, then 200 to 600 units/hour to maintain adequate anti-Xa levels. <b>Note:</b> If patient is &lt;55 kg, reduce bolus dose to 2,000 units, followed by 400 units/hour for 4 hours, then 150 to 400 units/hour to maintain anti-Xa levels of 500 to 1,000 units/L.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13162275\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950034\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Orgaran: 750 anti-Xa units/0.6 mL (0.6 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11218429\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802622\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV, SubQ: May administer intravenously as bolus or infusion, or by subcutaneous injection. When administered intravenously, do not mix with other drugs. For subcutaneous administration, rotate injection sites. Do <b>not </b>administer intramuscularly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156547\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Catheter patency:</b> Intermittent flushing to maintain patency of catheters/IV lines and/or access ports</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Deep vein thrombosis: </b>Prevention of postoperative deep vein thrombosis (DVT) following orthopedic or major abdominal and thoracic surgery; prevention of DVT in patients with confirmed diagnosis of non-hemorrhagic stroke</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heparin-induced thrombocytopenia:</b> Management of heparin-induced thrombocytopenia (HIT)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6052981\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Orgaran may be confused with argatroban</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156536\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined. As with all anticoagulants, bleeding is the major adverse effect of danaparoid. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3%), constipation (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary retention (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukocytosis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Hematoma at injection site (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation, cerebral infarction, decreased blood pressure (arterial), deep vein thrombosis, hypotension, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Cerebral hemorrhage, confusion, fatigue, hemiparesis, insomnia, loss of consciousness, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hematuria, urinary incontinence, urinary tract hemorrhage (including microscopic), urine abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise, hematoma, hemorrhage (dose-related), thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea, asthma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Increased serum alkaline phosphatase, increased serum ALT (transient), increased serum AST (transient)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156550\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to danaparoid, or any component of the formulation (including sulfites); history of thrombocytopenia while receiving danaparoid or when associated with a positive <i>in vitro</i> test for antiplatelet antibodies in the presence of danaparoid; hemorrhagic stroke (without systemic emboli); history of thrombosis with danaparoid; acute hemorrhagic stroke; major blood clotting disorder; uncontrollable active bleeding state; severe hemorrhagic diathesis; acute or subacute bacterial endocarditis; active gastric or duodenal ulcer; surgery of CNS, eyes, or ears; diabetic or hemorrhagic retinopathy; severe uncontrolled hypertension; other conditions or diseases that increase risk of hemorrhage; not for intramuscular use</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156533\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding (eg, severe hepatic disease, patients undergoing knee surgery or other invasive procedures, concomitant therapy with platelet inhibitors, elderly).  Discontinue if bleeding occurs. <b>Note:</b> Routine clotting assays are not suitable for monitoring danaparoid anticoagulant activity; determining anti-factor Xa levels is the only available method but may not correlate with efficacy. Danaparoid is <b>not</b> effectively antagonized by protamine sulfate. No other antidote is available, so extreme caution is needed in monitoring dose given and resulting factor Xa inhibition effect. Plasmapheresis may be effective in reducing anti-Xa levels in emergency situations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Monitor for hyperkalemia. Heparin can cause hyperkalemia by affecting aldosterone; similar reactions could occur with danaparoid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Use with caution in patients with a history of peptic ulcer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prosthetic heart valves: Safety and efficacy have not been established for use as thromboprophylaxis in patients with prosthetic heart valves.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; primarily renally eliminated. Dosage adjustment may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stroke: Hemorrhagic stroke should be ruled out by CT scan prior to initiating therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: Use caution in patients with or with a history of thrombocytopenia (heparin-induced, congenital) or platelet defects. The manufacturer labeling recommends that patients with a history of heparin-induced thrombocytopenia be tested for cross-reactivity with danaparoid prior to initiating therapy; if test is positive, alternative therapy should be employed unless otherwise not available. If danaparoid is administered, therapy must be discontinued immediately with clinical signs of positive cross-reactivity (eg, increased reduction in platelet counts, thrombosis, skin necrosis). May resume therapy (if needed) only after laboratory confirmed negative test for danaparoid activated antiplatelet antibodies. Cutaneous allergy tests may help detect the presence of cross-reactivity between heparins and danaparoid (Grassegger, 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Concurrent drug therapy issues:</b></i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>&bull; </i>Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium sulfite: This product contains sodium sulfite which may cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people; this is seen more frequently in asthmatics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuraxial anesthesia: <b>Spinal or epidural hematomas, including subsequent paralysis, may occur with recent or anticipated neuraxial anesthesia (epidural or spinal anesthesia) or spinal puncture in patients anticoagulated with LMWH or heparinoids.</b> Consider risk versus benefit prior to spinal procedures; risk is increased by the use of concomitant agents which may alter hemostasis, the use of indwelling epidural catheters for analgesia, a history of spinal deformity or spinal surgery, as well as a history of traumatic or repeated epidural or spinal punctures. Spinal procedures should be avoided for 12 hours after the last danaparoid dose; allow at least 2 hours after procedure before resuming danaparoid therapy. Patient should be observed closely for bleeding and signs and symptoms of neurological impairment if therapy is administered during or immediately following diagnostic lumbar puncture, epidural anesthesia, or spinal anesthesia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299123\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156538\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9320&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13161901\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. The manufacturer labeling states that incidental observations in pregnant women during the last trimesters, gave no indication that use during pregnancy results in fetal abnormalities or exacerbation of bleeding in the mother or infant during delivery. Use in pregnant women however is generally not recommended unless deemed medically necessary and alternative therapy is unavailable. Danaparoid does not cross the placenta and is the preferred anticoagulant in pregnant women with HIT (Guyatt 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13161913\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Only low amounts of anit-Xa activity have been found breast milk following maternal use of danaparoid; however, because it is not absorbed when taken orally, it is unlikely to cause adverse events in a nursing infant. Use of danaparoid may be continued in breast-feeding (Guyatt 2012). The manufacturer labeling recommends that women receiving danaparoid avoid breast-feeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156542\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Platelets (baseline, every other day during week 1, twice weekly during weeks 2 and 3, and once weekly thereafter); occult blood or other signs of bleeding; anti-Xa activity (if available). See manufacturer&rsquo;s recommendations within labeling regarding anticipated anti-Xa levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156532\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits factor Xa and IIa (anti-Xa effects &gt;20 times anti-IIa effects). Prevents fibrin formation in the coagulation pathway via thrombin generation inhibition. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156549\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peak effect: SubQ: Maximum antifactor Xa activities occur in 4-5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ: ~100%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Anti-Xa activity: ~25 hours (renal impairment: 29-35 hours); Thrombin generation inhibition activity: ~7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156552\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ogaran (KR);</li>\n      <li>Orgaran (AT, AU, BE, CH, DE, FI, FR, GB, GR, IT, LU, NL, NO, NZ, PT, SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Grassegger A, Fritsch P, and Reider N, &ldquo;Delayed-Type Hypersensitivity and Cross-Reactivity to Heparins and Danaparoid: A Prospective Study,&rdquo; Dermatol Surg, 2001, 27(1):47-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/danaparoid-united-states-not-available-drug-information/abstract-text/11231243/pubmed\" target=\"_blank\" id=\"11231243\">11231243</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/danaparoid-united-states-not-available-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linkins L, Dans AL, Moores LK, et al, &ldquo;Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e495-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/danaparoid-united-states-not-available-drug-information/abstract-text/22315270/pubmed\" target=\"_blank\" id=\"22315270\">22315270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orgaran (danaparoid) [product monograph DVT]. Toronto, Ontario, Canada: Aspen Pharmacare Canada Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orgaran (danaparoid) [product monograph HIT]. Kirkland, Quebec, Canada: Merck Canada Inc; May 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9320 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F156561\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F156590\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F156563\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F156580\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F156564\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F156565\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13162275\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950034\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11218429\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F802622\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F156547\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6052981\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156536\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156550\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156533\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299123\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156538\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13161901\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13161913\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F156542\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156532\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F156549\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F156552\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9320|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=danaparoid-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Danaparoid (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}